List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1235185/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Different Metabolic Responses of Human Brown Adipose Tissue to Activation by Cold and Insulin. Cell Metabolism, 2011, 14, 272-279.	16.2	609
2	Distribution of α2-adrenergic receptor subtype gene expression in rat brain. Molecular Brain Research, 1994, 21, 133-149.	2.3	398
3	Gene targeting — homing in on α2-adrenoceptor-subtype function. Trends in Pharmacological Sciences, 1997, 18, 211-219.	8.7	298
4	Dexmedetomidine, an α2-Adrenoceptor Agonist, Reduces Anesthetic Requirements for Patients Undergoing Minor Gynecologic Surgery. Anesthesiology, 1990, 73, 230-235.	2.5	256
5	Postoperative Pharmacokinetics and Sympatholytic Effects of Dexmedetomidine. Anesthesia and Analgesia, 1997, 85, 1136-1142.	2.2	247
6	Effects of dexmedetomidine, a selective α2-adrenoceptor agonist, on hemodynamic control mechanisms. Clinical Pharmacology and Therapeutics, 1989, 46, 33-42.	4.7	203
7	Neurochemical and behavioural changes in zebrafish <i>Danio rerio</i> after systemic administration of 6â€hydroxydopamine and 1â€methylâ€4â€phenylâ€1,2,3,6â€tetrahydropyridine. Journal of Neurochemistry, 88, 443-453.	20049	186
8	Adrenergic α _{2C} -Receptors Modulate the Acoustic Startle Reflex, Prepulse Inhibition, and Aggression in Mice. Journal of Neuroscience, 1998, 18, 3035-3042.	3.6	166
9	Bioavailability of dexmedetomidine after intranasal administration. European Journal of Clinical Pharmacology, 2011, 67, 825-831.	1.9	159
10	Genetic Alteration of α _{2C} -Adrenoceptor Expression in Mice: Influence on Locomotor, Hypothermic, and Neurochemical Effects of Dexmedetomidine, a Subtype-Nonselective α ₂ -Adrenoceptor Agonist. Molecular Pharmacology, 1997, 51, 36-46.	2.3	149
11	Test–retest reliability of 11C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 120-127.	6.4	130
12	α2-Adrenoceptor Regulation of Blood Glucose Homeostasis. Basic and Clinical Pharmacology and Toxicology, 2011, 108, 365-370.	2.5	114
13	Behavioural and neurochemical effects of antipamezole, a novel α2-adrenoceptor antagonist. European Journal of Pharmacology, 1988, 151, 35-42.	3.5	112
14	An insertion/deletion polymorphism in the α2b-adrenergic receptor gene is a novel genetic risk factor for acute coronary events. Journal of the American College of Cardiology, 2001, 37, 1516-1522.	2.8	110
15	Effects of Low and High Plasma Concentrations of Dexmedetomidine on Myocardial Perfusion and Cardiac Function in Healthy Male Subjects. Anesthesiology, 2006, 105, 902-910.	2.5	108
16	Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults—Randomized Controlled Trial. EBioMedicine, 2016, 13, 190-200.	6.1	108
17	Identification of a Three-Amino Acid Deletion in theα 2B-Adrenergic Receptor That Is Associated with Reduced Basal Metabolic Rate in Obese Subjects. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2429-2433.	3.6	103
18	Molecular Pharmacology of α ₂ -adrenoceptor Subtypes. Annals of Medicine, 1995, 27, 439-449.	3.8	100

#	Article	IF	CITATIONS
19	Variation in the alpha2B-adrenoceptorgene as a risk factor for prehospitalfatal myocardial infarction and sudden cardiac death. Journal of the American College of Cardiology, 2003, 41, 190-194.	2.8	97
20	α2-Adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the α2A-adrenoceptor subtype. Neuropharmacology, 2003, 44, 882-892.	4.1	91
21	Influence of hydroxychloroquine on the bioavailability of oral metoprolol. British Journal of Clinical Pharmacology, 2000, 49, 549-554.	2.4	89
22	Plasma 3, 4-dihydroxyphenylglycol (DHPG) and 3-methoxy-4- hydroxyphenylglycol (MHPG) are insensitive indicators of α2-adrenoceptor mediated regulation of norepinephrine release in healthy human volunteers. Life Sciences, 1991, 49, 75-84.	4.3	88
23	Postoperative Pharmacokinetics and Sympatholytic Effects of Dexmedetomidine. Anesthesia and Analgesia, 1997, 85, 1136-1142.	2.2	80
24	α2-Adrenoceptor regulation of adenylyl cyclase in CHO cells: Dependence on receptor density, receptor subtype and current activity of adenylyl cyclase. European Journal of Pharmacology, 1997, 335, 53-63.	3.5	78
25	Expression and function of alpha2-adrenoceptors in zebrafish: drug effects, mRNA and receptor distributions. Journal of Neurochemistry, 2005, 94, 1559-1569.	3.9	71
26	Longitudinal Amyloid Imaging in Mouse Brain with ¹¹ C-PIB: Comparison of APP23, Tg2576, and APP _{swe} -PS1 _{dE9} Mouse Models of Alzheimer Disease. Journal of Nuclear Medicine, 2013, 54, 1434-1441.	5.0	71
27	Effects of common polymorphisms in the $\hat{l}\pm 1A$ -, $\hat{l}\pm 2B$ -, \hat{l}^21 - and \hat{l}^22 -adrenoreceptors on haemodynamic responses to adrenaline. Clinical Science, 2003, 104, 509-520.	4.3	69
28	Coupling of human α2-adrenoceptor subtypes to regulation of cAMP production in transfected S115 cells. European Journal of Pharmacology, 1994, 266, 165-174.	2.6	68
29	Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study. The Lancet Gastroenterology and Hepatology, 2019, 4, 948-959.	8.1	65
30	Pharmacodynamics and pharmacokinetics of intramuscular dexmedetomidine. Clinical Pharmacology and Therapeutics, 1992, 52, 537-546.	4.7	64
31	Recombinant human α2-adrenoceptor subtypes: comparison of [3H]rauwolscine, [3H]atipamezole and [3H]RX821002 as radioligands. Biochimica Et Biophysica Acta - Molecular Cell Research, 1995, 1266, 207-214.	4.1	62
32	Application of cross-species PET imaging to assess neurotransmitter release in brain. Psychopharmacology, 2015, 232, 4129-4157.	3.1	61
33	Conserved structural, pharmacological and functional properties among the three human and five zebrafish α 2 -adrenoceptors. British Journal of Pharmacology, 2005, 144, 165-177.	5.4	60
34	Octopamine Receptors from the Barnacle Balanus improvisus Are Activated by the α ₂ -Adrenoceptor Agonist Medetomidine. Molecular Pharmacology, 2010, 78, 237-248.	2.3	60
35	Molecular Mechanism for Agonist-Promoted α _{2A} -Adrenoceptor Activation by Norepinephrine and Epinephrine. Molecular Pharmacology, 2001, 59, 1343-1354.	2.3	59
36	Nonradioactive GTP Binding Assay to Monitor Activation of G Protein-Coupled Receptors. Assay and Drug Development Technologies, 2003, 1, 275-280.	1.2	56

#	Article	IF	CITATIONS
37	Identification of Duplicated Fourth α2-Adrenergic Receptor Subtype by Cloning and Mapping of Five Receptor Genes in Zebrafish. Molecular Biology and Evolution, 2004, 21, 14-28.	8.9	56
38	Pharmacokinetics of [18F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1784-1795.	6.4	52
39	Sedation with Dexmedetomidine or Propofol Impairs Hypoxic Control of Breathing in Healthy Male Volunteers. Anesthesiology, 2016, 125, 700-715.	2.5	52
40	Receptor Subtype-Induced Targeting and Subtype-Specific Internalization of Human α2-Adrenoceptors in PC12 Cells. Journal of Neuroscience, 1999, 19, 9281-9288.	3.6	51
41	Influence of MK-467, a Peripherally Acting α ₂ -Adrenoceptor Antagonist on the Disposition of Intravenous Dexmedetomidine in Dogs. Drug Metabolism and Disposition, 2012, 40, 445-449.	3.3	49
42	Altered glucose homeostasis in α2A-adrenoceptor knockout mice. European Journal of Pharmacology, 2004, 505, 243-252.	3.5	47
43	Inhibition of α-adrenergic tone disturbs the distribution of blood flow in the exercising human limb. American Journal of Physiology - Heart and Circulatory Physiology, 2013, 305, H163-H172.	3.2	47
44	Subtype-specific stimulation of []GTPγS binding by recombinant α2-adrenoceptors. European Journal of Pharmacology, 1998, 355, 275-279.	3.5	46
45	CYP2A6 genetic variation and dexmedetomidine disposition. European Journal of Clinical Pharmacology, 2012, 68, 937-942.	1.9	42
46	Plasma drug concentrations and clinical effects of a peripheral alpha-2-adrenoceptor antagonist, MK-467, in horses sedated with detomidine. Veterinary Anaesthesia and Analgesia, 2013, 40, 257-264.	0.6	42
47	Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects. European Journal of Clinical Pharmacology, 2015, 71, 1197-1207.	1.9	42
48	Molecular mechanisms underlying mifepristone's agonistic action on ovarian cancer progression. EBioMedicine, 2019, 47, 170-183.	6.1	41
49	Molecular Pharmacology of α2-adrenoceptor Subtypes. Annals of Medicine, 1995, 27, 439-449.	3.8	41
50	Upper Airway Collapsibility during Dexmedetomidine and Propofol Sedation in Healthy Volunteers. Anesthesiology, 2019, 131, 962-973.	2.5	39
51	Cloning and expression of a fish α ₂ â€adrenoceptor. British Journal of Pharmacology, 1993, 110, 54-60.	5.4	38
52	Reduced blood glucose levels, increased insulin levels and improved glucose tolerance in α2A-adrenoceptor knockout mice. European Journal of Pharmacology, 2008, 578, 359-364.	3.5	38
53	Ethnic and Genetic Determinants of Cardiovascular Response to the Selective α 2 -Adrenoceptor Agonist Dexmedetomidine. Hypertension, 2008, 51, 406-411.	2.7	37
54	Disposition of single oral doses of E-10-hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects. Clinical Pharmacology and Therapeutics, 1986, 40, 261-267.	4.7	34

#	Article	IF	CITATIONS
55	Phenoxybenzamine Binding Reveals the Helical Orientation of the Third Transmembrane Domain of Adrenergic Receptors. Journal of Biological Chemistry, 2001, 276, 31279-31284.	3.4	34
56	Chloroethylclonidine and 2-Aminoethyl Methanethiosulfonate Recognize Two Different Conformations of the Human α2A-Adrenergic Receptor. Journal of Biological Chemistry, 1999, 274, 21867-21872.	3.4	33
57	Clinical effects and pharmacokinetic variables of romifidine and the peripheral α2â€adrenoceptor antagonist MKâ€467 in horses. Veterinary Anaesthesia and Analgesia, 2016, 43, 599-610.	0.6	33
58	Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects. Neuropsychopharmacology, 2019, 44, 1667-1673.	5.4	33
59	Pharmacokinetics and Sedative Effects of Intranasal Dexmedetomidine in Ambulatory Pediatric Patients. Anesthesia and Analgesia, 2020, 130, 949-957.	2.2	33
60	Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: Effects on hemodynamics and catecholamine metabolism in healthy volunteers*. Clinical Pharmacology and Therapeutics, 1996, 59, 450-457.	4.7	32
61	Chloroethylclonidine Binds Irreversibly to Exposed Cysteines in the Fifth Membrane-Spanning Domain of the Human α2A-Adrenergic Receptor. Molecular Pharmacology, 1998, 53, 370-376.	2.3	32
62	Three-dimensional Models of α2A-Adrenergic Receptor Complexes Provide a Structural Explanation for Ligand Binding. Journal of Biological Chemistry, 1999, 274, 23405-23413.	3.4	31
63	Model structures of α-2 adrenoceptors in complex with automatically docked antagonist ligands raise the possibility of interactions dissimilar from agonist ligands. Journal of Structural Biology, 2005, 150, 126-143.	2.8	30
64	Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. European Journal of Clinical Pharmacology, 2015, 71, 321-327.	1.9	30
65	Foundations of Human Consciousness: Imaging the Twilight Zone. Journal of Neuroscience, 2021, 41, 1769-1778.	3.6	30
66	Effects of variation in the human α _{2A} ―and α _{2C} â€adrenoceptor genes on cognitive tasks and pain perception. European Journal of Pain, 2010, 14, 154-159.	2.8	29
67	Molecular mechanisms of ligand-receptor interactions in transmembrane domain V of the α 2A -adrenoceptor. British Journal of Pharmacology, 2003, 140, 347-358.	5.4	28
68	Effect of α2B-Adrenoceptor Polymorphism on Peripheral Vasoconstriction in Healthy Volunteers. Anesthesiology, 2005, 102, 536-542.	2.5	28
69	Loss of amitriptyline analgesia in α2A-adrenoceptor deficient mice. European Journal of Pharmacology, 2004, 485, 193-196.	3.5	27
70	Genetic Variations in the α _{2A} -Adrenoreceptor Are Associated With Blood Pressure Response to the Agonist Dexmedetomidine. Circulation: Cardiovascular Genetics, 2011, 4, 179-187.	5.1	27
71	Stable expression of recombinant human α2-adrenoceptor subtypes in two mammalian cell lines: characterization with [3H]rauwolscine binding, inhibition of adenylate cyclase and RNase protection assay. Biochimica Et Biophysica Acta - Molecular Cell Research, 1992, 1134, 169-177.	4.1	25
72	Rifampicin markedly decreases the exposure to oral and intravenous tramadol. European Journal of Clinical Pharmacology, 2013, 69, 1293-1301.	1.9	25

#	Article	IF	CITATIONS
73	Detomidine and the combination of detomidine and MK-467, a peripheral alpha-2 adrenoceptor antagonist, as premedication in horses anaesthetized with isoflurane. Veterinary Anaesthesia and Analgesia, 2015, 42, 527-536.	0.6	25
74	The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine*. Clinical Pharmacology and Therapeutics, 1995, 58, 221-227.	4.7	24
75	Ligand-induced α2-adrenoceptor endocytosis: relationship to Gi protein activation. Biochemical and Biophysical Research Communications, 2004, 321, 226-233.	2.1	24
76	Functional assessment of recombinant human α2-adrenoceptor subtypes with Cytosensor microphysiometry. European Journal of Pharmacology, 1999, 385, 247-253.	3.5	23
77	Plasma concentration and cardiovascular effects of intramuscular medetomidine combined with three doses of the peripheral alpha2-antagonist MK-467 in dogs. Veterinary Anaesthesia and Analgesia, 2017, 44, 417-426.	0.6	23
78	α2-Adrenoceptor agonists stimulate high-affinity GTPase activity in a receptor subtype-selective manner. European Journal of Pharmacology, 1999, 374, 137-146.	3.5	22
79	Dietary sodium modulates the interaction between efferent and afferent renal nerve activity by altering activation of α ₂ -adrenoceptors on renal sensory nerves. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 300, R298-R310.	1.8	22
80	In vivo PET imaging of beta-amyloid deposition in mouse models of Alzheimer's disease with a high specific activity PET imaging agent [18F]flutemetamol. EJNMMI Research, 2014, 4, 37.	2.5	22
81	The effect of an apple polyphenol extract rich in epicatechin and flavan-3-ol oligomers on brachial artery flow-mediated vasodilatory function in volunteers with elevated blood pressure. Nutrition Journal, 2017, 16, 73.	3.4	22
82	A PET Tracer for Brain α _{2C} Adrenoceptors, ¹¹ C-ORM-13070: Radiosynthesis and Preclinical Evaluation in Rats and Knockout Mice. Journal of Nuclear Medicine, 2014, 55, 1171-1177.	5.0	21
83	Functional expression and direct visualization of the human α2B-adrenergic receptor and α2B-AR-green fluorescent fusion protein in mammalian cell using Semliki Forest virus vectors. Protein Expression and Purification, 2003, 32, 265-275.	1.3	20
84	Safety, Biodistribution, and Radiation Dosimetry of ¹⁸ F-rhPSMA-7.3 in Healthy Adult Volunteers. Journal of Nuclear Medicine, 2021, 62, 679-684.	5.0	20
85	Detomidine Reduces the Plasma Catecholamine, but not Cortisol Concentrations in Horses. Transboundary and Emerging Diseases, 1991, 38, 153-156.	0.6	19
86	Determination of Conjugated Dopamine in Cerebrospinal Fluid from Humans and Nonâ€human Primates with High Performance Liquid Chromatography using Electrochemical Detection. Acta Pharmacologica Et Toxicologica, 1984, 55, 88-94.	0.0	18
87	Agonist-dependent trafficking of α2-adrenoceptor subtypes: dependence on receptor subtype and employed agonist. European Journal of Cell Biology, 2003, 82, 231-239.	3.6	18
88	α ₂ -Adrenoreceptors Profile Modulation. 4. From Antagonist to Agonist Behavior. Journal of Medicinal Chemistry, 2008, 51, 4289-4299.	6.4	18
89	3-[(Imidazolidin-2-yl)imino]indazole ligands with selectivity for the α2-adrenoceptor compared to the imidazoline I1 receptor. Bioorganic and Medicinal Chemistry, 2011, 19, 321-329.	3.0	18
90	Alpha-2B adrenoceptor polymorphism and peripheral vasoconstriction. Pharmacogenetics and Genomics, 2005, 15, 357-363.	1.5	17

#	Article	IF	CITATIONS
91	Tolerability of ORMâ€12741 and effects on episodic memory in patients with Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 1-9.	3.7	17
92	Reduced Turnover of Dopamine and 5â€Hydroxytryptamine in Discrete Dopaminergic, Noradrenergic and Serotonergic Rat Brain Areas after Acutely Administered Medetomidine, a Selective α ₂ â€Adrenoceptor Agonist. Basic and Clinical Pharmacology and Toxicology, 1993, 72, 182-187.	0.0	16
93	11C-ORM-13070, a novel PET ligand for brain α2C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1947-1956.	6.4	16
94	Antenatal Dexamethasone Treatment Decreases Plasma Catecholamine Levels in Preterm Infants. Pediatric Research, 1998, 43, 801-807.	2.3	16
95	Cloning, characterisation and identification of several polymorphisms in the promoter region of the human 1±2B-adrenergic receptor gene. Biochemical Pharmacology, 2004, 67, 469-478.	4.4	15
96	Involvement of α ₂ -Adrenoceptor Subtypes A and C in Glucose Homeostasis and Adrenaline-Induced Hyperglycaemia. Neuroendocrinology, 2012, 96, 51-59.	2.5	15
97	Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction. European Journal of Clinical Pharmacology, 2013, 69, 867-875.	1.9	15
98	A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin. Bioorganic and Medicinal Chemistry, 2016, 24, 3174-3183.	3.0	15
99	Differential Internalization Rates and Postendocytic Sorting of the Norepinephrine and Dopamine Transporters Are Controlled by Structural Elements in the N Termini. Journal of Biological Chemistry, 2016, 291, 5634-5651.	3.4	15
100	Gene expression profiles and signaling mechanisms in α2B-adrenoceptor-evoked proliferation of vascular smooth muscle cells. BMC Systems Biology, 2017, 11, 65.	3.0	15
101	Alpha2C-adrenoceptor mediated regulation of cortical EEG arousal. Neuropharmacology, 2002, 43, 1305-1312.	4.1	14
102	Fluorinated analogues of marsanidine, a highly α2-AR/imidazoline I1 binding site-selective hypotensive agent. Synthesis and biological activities. European Journal of Medicinal Chemistry, 2014, 87, 386-397.	5.5	14
103	Validation of <scp>[¹¹C]ORMâ€13070</scp> as a <scp>PET</scp> tracer for alpha _{2c} â€adrenoceptors in the human brain. Synapse, 2015, 69, 172-181.	1.2	14
104	Transfer of SAR information from hypotensive indazole to indole derivatives acting at α-adrenergic receptors: InÂvitro and inÂvivo studies. European Journal of Medicinal Chemistry, 2016, 115, 406-415.	5.5	14
105	Speech is special: The stress effects of speech, noise, and silence during tasks requiring concentration. Indoor Air, 2021, 31, 264-274.	4.3	14
106	[Ethyl-3H]RS-79948-197 α2-adrenoceptor autoradiography validation in α2-adrenoceptor knockout mice. European Journal of Pharmacology, 2004, 497, 301-309.	3.5	13
107	Variation in the $\hat{1}\pm 2A$ adrenoceptor gene and the effect of dexmedetomidine on plasma insulin and glucose. Pharmacogenetics and Genomics, 2013, 23, 479-486.	1.5	13
108	Amphetamine Decreases Â2C-Adrenoceptor Binding of [11C]ORM-13070: A PET Study in the Primate Brain. International Journal of Neuropsychopharmacology, 2015, 18, pyu081-pyu081.	2.1	13

#	Article	IF	CITATIONS
109	Effects of the α2-adrenoceptor agonist medetomidine on the distribution and clearance of alfaxalone during coadministration by constant rate infusion in dogs. American Journal of Veterinary Research, 2017, 78, 956-964.	0.6	13
110	Sedative Plasma Concentrations and Delirium Risk in Critical Illness. Annals of Pharmacotherapy, 2018, 52, 513-521.	1.9	13
111	The single dose pharmacokinetics and safety of deramciclane in healthy male volunteers. , 1999, 20, 327-334.		12
112	Constitutive precoupling to Gi and increased agonist potency in the α2B-adrenoceptor. Biochemical and Biophysical Research Communications, 2003, 306, 959-965.	2.1	12
113	Sublingual administration of detomidine to calves prior to disbudding: a comparison with the intravenous route. Veterinary Anaesthesia and Analgesia, 2014, 41, 372-377.	0.6	12
114	Sensitivity of [11C]ORM-13070 to increased extracellular noradrenaline in the CNS – a PET study in human subjects. Psychopharmacology, 2015, 232, 4169-4178.	3.1	12
115	Safety, Tolerability, and Antihypertensive Effect of SER100, an Opiate Receptorâ€Like 1 (ORLâ€1) Partial Agonist, in Patients With Isolated Systolic Hypertension. Clinical Pharmacology in Drug Development, 2017, 6, 584-591.	1.6	12
116	Peripheral Î ± 2 -adrenoceptor antagonism affects the absorption of intramuscularly coadministered drugs. Veterinary Anaesthesia and Analgesia, 2018, 45, 405-413.	0.6	12
117	Blood pressure regulation and cardiac autonomic control in mice overexpressing α- and γ-melanocyte stimulating hormone. Peptides, 2008, 29, 1943-1952.	2.4	11
118	Homogeneous GTP Binding Assay Employing QRET Technology. Journal of Biomolecular Screening, 2010, 15, 261-267.	2.6	11
119	Synthesis and biological activities of 2-[(heteroaryl)methyl]imidazolines. Bioorganic and Medicinal Chemistry, 2012, 20, 108-116.	3.0	11
120	Amino Acid Plasma Profiles from a Prolonged-Release Protein Substitute for Phenylketonuria: A Randomized, Single-Dose, Four-Way Crossover Trial in Healthy Volunteers. Nutrients, 2020, 12, 1653.	4.1	11
121	Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene. Biopharmaceutics and Drug Disposition, 2013, 34, 387-395.	1.9	10
122	Detecting a dexmedetomidine-evoked reduction of noradrenaline release in the human brain with the alpha2C-adrenoceptor PET ligand [11C]ORM-13070. Synapse, 2016, 70, 57-65.	1.2	10
123	Effects of the peripherally acting α2-adrenoceptor antagonist MK-467 on cardiopulmonary function in sheep sedated by intramuscular administration of medetomidine and ketamine and reversed by intramuscular administration of atipamezole. American Journal of Veterinary Research, 2018, 79, 921-932	0.6	10
124	Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3723-3731.	6.4	10
125	Non-adrenergic binding of [3 H]atipamezole in rat kidney-regional distribution and comparison to α2 -adrenoceptors. British Journal of Pharmacology, 1999, 128, 1215-1222.	5.4	9
126	Identification of a novel 12-nucleotide insertion polymorphism in the promoter region of ADRA2B: Full linkage with the 9-nucleotide deletion in the coding region and influence on transcriptional activity. Biochemical Pharmacology, 2010, 79, 407-412.	4.4	9

#	Article	IF	CITATIONS
127	Might the observed α2A-adrenoreceptor agonism or antagonism of allyphenyline analogues be ascribed to different molecular conformations?. Bioorganic and Medicinal Chemistry, 2012, 20, 2082-2090.	3.0	9
128	Effects of Ospemifene on Drug Metabolism Mediated by Cytochrome P450 Enzymes in Humans in Vitro and in Vivo. International Journal of Molecular Sciences, 2013, 14, 14064-14075.	4.1	9
129	Oral bioavailability of ospemifene improves with food intake. International Journal of Clinical Pharmacology and Therapeutics, 2013, 51, 787-794.	0.6	9
130	Single-dose and steady-state pharmacokinetics of ospemifene, a selective estrogen receptor modulator, in postmenopausal women. International Journal of Clinical Pharmacology and Therapeutics, 2013, 51, 861-867.	0.6	9
131	High-throughput screening with a miniaturized radioligand competition assay identifies new modulators of human α2-adrenoceptors. European Journal of Pharmaceutical Sciences, 2012, 47, 941-951.	4.0	8
132	Placental and Blood SF Transfer of Intramuscularly Administered Atropine in the same Person. Basic and Clinical Pharmacology and Toxicology, 1987, 60, 108-109.	0.0	7
133	Expression and characterization of the human α2B-adrenoceptor in a vascular smooth muscle cell line. European Journal of Pharmacology, 2008, 587, 48-56.	3.5	7
134	Cardiovascular effects of premedication with medetomidine alone and in combination with MK-467 or glycopyrrolate in dogs subsequently anesthetized with isoflurane. American Journal of Veterinary Research, 2017, 78, 1245-1254.	0.6	7
135	Premedication with intranasal dexmedetomidine decreases barbiturate requirement in pediatric patients sedated for magnetic resonance imaging: a retrospective study. BMC Anesthesiology, 2019, 19, 22.	1.8	7
136	Effects of remifentanil on pharyngeal swallowing and esophageal motility: no impact of different bolus volumes and partial antagonism by methylnaltrexone. American Journal of Physiology - Renal Physiology, 2021, 321, G367-G377.	3.4	7
137	α2B-Adrenoceptor levels govern agonist and inverse agonist responses in PC12 cells. Biochemical and Biophysical Research Communications, 2003, 308, 12-18.	2.1	6
138	Dorsal hand vein responses to the α1-adrenoceptor agonist phenylephrine do not predict responses to the α2-adrenoceptor agonist dexmedetomidine. European Journal of Pharmacology, 2011, 653, 70-74.	3.5	6
139	Increased Energy Expenditure, Lipolysis and Hyperinsulinemia Confer Resistance to Central Obesity and Type 2 Diabetes in Mice Lacking Alpha2α-Adrenoceptors. Neuroendocrinology, 2018, 107, 324-339.	2.5	6
140	Cardiovascular and sedation reversal effects of intramuscular administration of atipamezole in dogs treated with medetomidine hydrochloride with or without the peripheral α2-adrenoceptor antagonist vatinoxan hydrochloride. American Journal of Veterinary Research, 2019, 80, 912-922.	0.6	6
141	Assessing an Electronic Health Record research platform for identification of clinical trial participants. Contemporary Clinical Trials Communications, 2021, 21, 100692.	1.1	6
142	Nitrogen Balance after the Administration of a Prolonged-Release Protein Substitute for Phenylketonuria as a Single Dose in Healthy Volunteers. Nutrients, 2021, 13, 3189.	4.1	6
143	Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2011, 55, 265-79.	0.7	6
144	Assessment of $\hat{I}\pm 2$ -adrenoceptor antagonist potency with GTPase assay. European Journal of Pharmacology, 1997, 338, 293-296.	3.5	5

#	Article	IF	CITATIONS
145	A polymorphism in the protein kinase C gene PRKCB is associated with α2-adrenoceptor-mediated vasoconstriction. Pharmacogenetics and Genomics, 2013, 23, 127-134.	1.5	5
146	PET in drug discovery and development: an introduction. Annals of Medicine, 1999, 31, 430-431.	3.8	4
147	Antinociceptive Synergism of MDâ€354 and Clonidine. Part II. The α ₂ â€Adrenoceptor Component. Basic and Clinical Pharmacology and Toxicology, 2010, 107, 690-697.	2.5	4
148	Quantitative determination of α2B-adrenoceptor-evoked myosin light chain phosphorylation in vascular smooth muscle cells. Journal of Pharmacological and Toxicological Methods, 2014, 70, 152-162.	0.7	4
149	Potentiation of Glibenclamide Hypoglycaemia in Mice by MKâ€467, a Peripherally Acting Alpha2â€Adrenoceptor Antagonist. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 392-398.	2.5	4
150	Radiosynthesis and Preclinical Evaluation of an α2A-Adrenoceptor Tracer Candidate, 6-[18F]Fluoro-marsanidine. Molecular Imaging and Biology, 2019, 21, 879-887.	2.6	4
151	Treating gambling disorder with as needed administration of intranasal naloxone: a pilot study to evaluate acceptability, feasibility and outcomes. BMJ Open, 2019, 9, e023728.	1.9	4
152	Population Modelling of Dexmedetomidine Pharmacokinetics and Haemodynamic Effects After Intravenous and Subcutaneous Administration. Clinical Pharmacokinetics, 2020, 59, 1467-1482.	3.5	4
153	Candida antarctica Lipase A-Based Enantiorecognition of a Highly Strained 4-Dibenzocyclooctynol (DIBO) Used for PET Imaging. Molecules, 2020, 25, 879.	3.8	4
154	Investigation of the effects of vatinoxan on somatic and visceral antinociceptive efficacy of medetomidine in dogs. American Journal of Veterinary Research, 2020, 81, 299-308.	0.6	4
155	Application of the PET ligand [11C]ORM-13070 to examine receptor occupancy by the α2C-adrenoceptor antagonist ORM-12741: translational validation of target engagement in rat and human brain. EJNMMI Research, 2020, 10, 152.	2.5	4
156	Acute stress effects of impulsive noise during mental work. Journal of Environmental Psychology, 2022, 81, 101819.	5.1	4
157	Hormonal, Haemodynamic, and Subjective Effects of Intravenously Infused Indomethacin: No Change in the Physiological Response to Hypertonic Saline Challenge. Basic and Clinical Pharmacology and Toxicology, 1989, 65, 231-235.	0.0	3
158	Intracellularly Truncated Human α2B-Adrenoceptors: Stable and Functional GPCRs for Structural Studies. Journal of Receptor and Signal Transduction Research, 2005, 25, 99-124.	2.5	3
159	Evidence that the multiflorineâ€derived substituted quinazolidine 55P0251 augments insulin secretion and lowers blood glucose via antagonism at α ₂ â€adrenoceptors in mice. Diabetes, Obesity and Metabolism, 2020, 22, 290-302.	4.4	3
160	Effects of intramuscular vatinoxan (MK-467), co-administered with medetomidine and butorphanol, on cardiopulmonary and anaesthetic effects of intravenous ketamine in dogs. Veterinary Anaesthesia and Analgesia, 2020, 47, 604-613.	0.6	3
161	Uptake of ¹⁸ F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 205-213.	1.0	3
162	Monoamine Metabolite Levels in Rat CSF: Kinetic Studies. Basic and Clinical Pharmacology and Toxicology, 1987, 61, 167-171.	0.0	2

#	Article	IF	CITATIONS
163	Comparison of simultaneous measurement of mouse locomotor activity by radiotelemetry and photobeam methods. Journal of Pharmacological and Toxicological Methods, 2015, 71, 90-94.	0.7	1
164	Effect of oral KETOPROFEN treatment in acute respiratory disease outbreaks in finishing pigs. Porcine Health Management, 2018, 4, 7.	2.6	1
165	Pharmacodynamic and pharmacokinetic profile of SMâ€1, a tripleâ€drug combination to increase total sleep time. Human Psychopharmacology, 2019, 34, e2716.	1.5	1
166	Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial. Trials, 2021, 22, 44.	1.6	1
167	Title is missing!. Biotechnology Letters, 2000, 22, 1963-1966.	2.2	0
168	Reply to "Letter to the editor: â€`Deconstructing the dogma of sympathetic restraint and its role in the cardiovascular response to exercise'― American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H464-H464.	3.2	0
169	Imaging of α2C-adrenoceptors in the living brain: a method to monitor noradrenaline release?. SpringerPlus, 2015, 4, L20.	1.2	0
170	The role of active transport in the transcellular movement of the peripheral α-adrenoceptor antagonist, MK-467: An pilot study. Canadian Journal of Veterinary Research, 2017, 81, 318-320.	0.2	0